Can a patient safely use basal insulin glargine together with dapagliflozin and empagliflozin (Jardiance) simultaneously?

Yes, a patient can safely use basal insulin glargine together with dapagliflozin and empagliflozin (Jardiance) simultaneously.

This combination is explicitly supported by current guidelines and is commonly used in clinical practice, though you should note that dapagliflozin and empagliflozin are both SGLT2 inhibitors—meaning they are from the same drug class and should NOT be used together. I believe your question may be asking whether insulin glargine can be combined with either dapagliflozin or empagliflozin, not both SGLT2 inhibitors at once.

Clarifying the Combination

Insulin Glargine + One SGLT2 Inhibitor (Either Dapagliflozin OR Empagliflozin): Safe and Recommended

• Guidelines explicitly support combining basal insulin with SGLT2 inhibitors 1, 2, 1
• The 2022 ADA/KDIGO consensus recommends SGLT2 inhibitors for most patients with type 2 diabetes and CKD (eGFR ≥20 ml/min/1.73 m²), independent of other glucose-lowering medications including insulin 1
• SGLT2 inhibitors provide cardiovascular and renal benefits beyond glucose control, making them valuable additions even when glycemic targets are already met 1, 2

Using Both Dapagliflozin AND Empagliflozin Together: Not Appropriate

• Both are SGLT2 inhibitors with identical mechanisms of action
• There is no clinical rationale or evidence for combining two drugs from the same class
• This would increase costs and adverse event risks without additional benefit

Key Management Considerations When Combining Insulin with SGLT2 Inhibitors

Insulin Dose Adjustment

When adding an SGLT2 inhibitor to existing insulin therapy, consider reducing the insulin dose by approximately 20% to prevent hypoglycemia 2. The 2018 ACC Expert Consensus specifically warns against substantial initial insulin reductions (>20%) to avoid diabetic ketoacidosis risk 2.

• For patients on complex insulin regimens or with labile glucose control, initiate the SGLT2 inhibitor in collaboration with the diabetes care provider 2
• Monitor blood glucose closely during the first weeks after adding the SGLT2 inhibitor
• Patients requiring only oral medications are at lower risk and may not need insulin dose adjustment 2

Critical Safety Monitoring

Diabetic Ketoacidosis (DKA) Risk:

• SGLT2 inhibitors carry a risk of euglycemic DKA (ketoacidosis even with blood glucose <250 mg/dL) 1, 2, 3, 4
• Maintain at least a low-dose insulin in insulin-requiring individuals—never discontinue insulin entirely 1
• Educate patients about DKA symptoms: nausea, vomiting, abdominal pain, weakness, trouble breathing 2, 3
• Institute a "sick day protocol"—hold SGLT2 inhibitors during acute illness 1
• If DKA symptoms develop, check ketones even if blood glucose is normal 3

Volume Depletion:

• Monitor for hypovolemia, especially in elderly patients or those on diuretics 1
• Consider proactive diuretic dose reduction in high-risk patients 1

Genital Mycotic Infections:

• Counsel on genital hygiene 1
• More common but typically manageable with topical antifungals 2

Hypoglycemia:

• Risk increases when SGLT2 inhibitors are combined with insulin or sulfonylureas 1, 2, 4
• Adjust background glucose-lowering agents appropriately 1

Clinical Evidence Supporting This Combination

Multiple studies demonstrate the safety and efficacy of combining SGLT2 inhibitors with basal insulin:

• Research shows significant HbA1c reductions (approximately 0.8-1.6%) when adding SGLT2 inhibitors to insulin therapy 5, 6, 7
• Weight loss of 3-8 kg is commonly observed 5, 8, 6, 7
• Insulin dose requirements typically decrease by 10-20% 5, 8, 9
• The combination improves glycemic variability and time-in-range 6
• Cardiovascular and renal benefits are maintained regardless of background insulin therapy 1, 2

Practical Algorithm for Implementation

1. Assess baseline status:

   • Check eGFR (must be ≥20 ml/min/1.73 m² for SGLT2 inhibitor initiation) 1
   • Evaluate volume status, especially in elderly or those on diuretics 1
   • Review current insulin regimen complexity

2. Initiate SGLT2 inhibitor:

   • Choose either dapagliflozin 10 mg daily OR empagliflozin 10-25 mg daily (not both)
   • Reduce total daily insulin dose by approximately 20% 2
   • For complex insulin regimens, coordinate with diabetes specialist 2

3. Patient education:

   • DKA symptoms and when to seek care 2, 3
   • Sick day protocol (hold SGLT2 inhibitor during illness) 1
   • Genital hygiene practices 1
   • Hypoglycemia recognition and management 2

4. Monitoring schedule:

   • Blood glucose monitoring intensively for first 2-4 weeks
   • Reassess insulin doses based on glucose patterns
   • Check eGFR every 3-6 months if <60 ml/min/1.73 m² 1
   • Monitor for adverse events (infections, volume depletion)

5. Long-term management:

   • Continue SGLT2 inhibitor even if eGFR falls below initiation threshold (unless not tolerated or on dialysis) 1
   • Maintain at least low-dose insulin in insulin-dependent patients 1
   • Reassess and adjust therapy every 3-6 months

Common Pitfalls to Avoid

• Never use two SGLT2 inhibitors together (dapagliflozin + empagliflozin)—choose one
• Never completely discontinue insulin when adding an SGLT2 inhibitor in insulin-dependent patients 1
• Don't reduce insulin by >20% initially to avoid DKA risk 2
• Don't continue SGLT2 inhibitors during acute illness—implement sick day protocols 1
• Don't ignore volume status in elderly or diuretic-treated patients 1